University of Liverpool Confidence in Concept Program – Enhancing Translation
Lead Research Organisation:
University of Liverpool
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
Publications
Al Fayi M
(2016)
The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance
in Oncotarget
Alhamdi Y
(2015)
Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection
in PLOS Pathogens
Arecco N
(2016)
Elastase levels and activity are increased in dystrophic muscle and impair myoblast cell survival, proliferation and differentiation.
in Scientific reports
Bricio-Moreno L
(2017)
Comparative Genomic Analysis and In Vivo Modeling of Streptococcus pneumoniae ST3081 and ST618 Isolates Reveal Key Genetic and Phenotypic Differences Contributing to Clonal Replacement of Serotype 1 in The Gambia
in The Journal of Infectious Diseases
Byrne A
(2018)
A case study of the challenges for an integrative practitioner learning a new psychological therapy
in Counselling and Psychotherapy Research
Fisher PL
(2017)
Metacognitive Therapy for Emotional Distress in Adult Cancer Survivors: A Case Series.
in Cognitive therapy and research
Forootan Farzad S.
(2016)
Fatty acid activated PPAR? promotes tumorigenicity of prostate cancer cells by up regulating
VEGF via PPAR responsive elements of the promoter
in ONCOTARGET
Hagen R
(2017)
Metacognitive Therapy for Depression in Adults: A Waiting List Randomized Controlled Trial with Six Months Follow-Up.
in Frontiers in psychology
Kawaguchi K
(2016)
High expression of Fatty Acid-Binding Protein 5 promotes cell growth and metastatic potential of colorectal cancer cells.
in FEBS open bio
Kawaguchi K
(2016)
The cancer-promoting gene fatty acid-binding protein 5 (FABP5) is epigenetically regulated during human prostate carcinogenesis.
in The Biochemical journal
Lomakina O
(2017)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two Genoa, Italy. 28 September - 01 October 2016
in Pediatric Rheumatology
Smith EM
(2017)
International validation of a urinary biomarker panel for identification of active lupus nephritis in children.
in Pediatric nephrology (Berlin, Germany)
Walker LE
(2017)
Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy.
in The Journal of clinical investigation
| Description | Clinical Development of an Ultrasensitive OCT Device to Improve the Management of Eye Disease |
| Amount | £1,338,299 (GBP) |
| Funding ID | II-LA-1116-20008 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2017 |
| End | 10/2020 |
| Description | Development of New Low Cost Point of Care Diagnostic Technologies for Diabetic Retinopathy in China |
| Amount | £1,150,450 (GBP) |
| Funding ID | EP/R014094/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2021 |
| Description | The role of immune tolerance and regulation in pneumococcal carriage and invasive disease. |
| Amount | £1,584,521 (GBP) |
| Funding ID | MR/P011284/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 05/2022 |
| Title | CANCER TREATMENT |
| Description | Provided is the use of inactivated FABP5 proteins, or fragments or variants thereof, as a medicament. These may be used in the treatment of a FABP5 mediated disorders, such as cancer. The inactivated FABP5 proteins, or fragments or variants thereof, may also be used in therapeutically reducing PPARY activation. The treatments of the invention are particularly useful in treating prostate cancer, and in inhibiting metastasis associated with this disease. A suitable inactivated FABP5 protein, or fragment or variant thereof, may incorporate mutations in amino acid residues associated with long chain fatty acid binding, such as Arg 109 and/or Arg 129. |
| IP Reference | WO2017103625 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | Translational grant; Chinese Govt; £120K |
| Title | MUSCLE REGENERATION |
| Description | The invention provides anelastase inhibitorfor use in the promotion of muscle regeneration in the treatment of a myopathy, as well as a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providing the subject with a therapeutically effective amount of an elastase inhibitor. Further provided is a pharmaceutical composition comprising anelastase inhibitorfor use in the promotion of muscle regeneration in the treatment of a myopathy. Elastase inhibitors may have a protective effect on muscle progenitor cells and their regenerative potential, which aids muscle cellregeneration. Byprotecting regenerative potential of muscle progenitor cells, elastase inhibitors enable or enhance the grown of new or existing muscle fibres. |
| IP Reference | WO2017194975 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | we are developing talks with a pharma company that specialises in the development of therapies for DMD (Solid Biosciences). |
| Title | OPTICAL INTERFEROMETRY APPARATUS AND METHOD |
| Description | Embodiments of the present invention provide a method and apparatus for frequency-domain optical interferometry imaging. Embodiments of the invention include an apparatus comprising a line- shaping optical element for directing optical radiation into a line illumination, an imaging optical element for receiving optical radiation comprising radiation reflected from a target sample and a reference point associated with the target sample,and a detection unit for measuring common path interferences between a plurality of reflections from the target sample and the reference point. Embodiments of the invention include a method comprising directing radiation into a line illumination, directing the line illumination towards a target sample, receiving radiation reflected from the target sample at a detection unit,and measuring common path interferences between a plurality of reflections at the target sample and a reference point. |
| IP Reference | WO2017168181 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | Novel OCT instrumentation was designed and built with promising performance for future clinical benefit. New software programs were developed to operate the new OCT device and support data acquisition and image analysis for accurately computing lens power. |
| Title | PHARMACOLOGICALLY ACTIVE COMPOUNDS |
| Description | wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them. |
| IP Reference | US2019084993 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | The project created valuable IP (category: Composition-of-Matter, newly synthesised compounds) which is exclusively owned by the University of Liverpool. US patent (No. 9676786) as well as European patent (No. 3087055) have been granted. We are currently in licensing negotiations (heads-of-terms stage) with two large pharmaceutical companies and in the process of contacting a suitable venture capital investor. |